Infigratinib met the primary endpoint in the phase 3 Propel 3 trial in achondroplasia. It drug demonstrated statistically significant improvements in annualized height velocity and body proportionality. Analysts characterized the data as a “best-case scenario,” strengthening the case for premium pricing. Regulatory submission is expected in the second half of the year amid increasing competition in the dwarfism market.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...